RxDoctor Payments Data

Matthew Hanserd, MD

Internal Medicine · Athens, ALNPI 1942524434

Payments from drug & device makers

$1,641in general payments, 2019–2025

Across 50 payments — averaging $32.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$509
  • Pfizer$321
  • Johnson & Johnson$318
  • Janssen Scientific Affairs, LLC$198
  • Globus Medical$146
  • E.r. Squibb & Sons, L.L.C.$39
  • plus $111 from 5 others

What the payments were for

  • Food & beverage$1,641100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,641 in reported general payments places this provider in the 65th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$198,431
Medicare patients
745
Services billed
2,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban526$82,139
XareltoRivaroxaban159$25,536
NuedextaDextromethorphan Hbr/Quinidine52$20,451
JardianceEmpagliflozin107$16,126
FycompaPerampanel26$15,795
EntrestoSacubitril/Valsartan82$14,957
Pantoprazole Sodium1,339$11,715
Potassium Chloride1,193$11,143
Atorvastatin Calcium1,207$10,602
JanuviaSitagliptin Phosphate58$8,227
Levothyroxine Sodium1,430$8,204
Lacosamide39$7,226
SpsSodium Polystyrene Sulfon/Sorb48$7,160
GemtesaVibegron57$6,766
LinzessLinaclotide11$6,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$321$82,139526 claims
Johnson & JohnsonXarelto$318$25,536159 claims
Avanir Pharmaceuticals, Inc.Nuedexta$12$20,45152 claims
AbbVieLinzess$18$6,46611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →